|
| Press Releases |
|
 |
|
| Monday, March 13, 2017 |
|
|
雅各臣公布收购康宁行70%权益 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业－雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天公布收购康宁行集团（包括「康宁行有限公司」及其香港附属公司）的70%权益，总代价为56,000,000港元。 more info >> |
|
|
雅各臣公布收購康寧行70%權益 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業－雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天公佈收購康寧行集團（包括「康寧行有限公司」及其香港附屬公司）的70%權益，總代價為56,000,000港元。完成收購後，康寧行集團將成為雅各臣間接非全資附屬公司。
more info >> |
|
|
Jacobson Pharma Announces Acquisition of 70% Interest in Hong Ning Hong |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production more info >> |
|
| Wednesday, January 18, 2017 |
|
|
雅各臣收购「十灵丹」、「十灵油」及「伤风克」建立具扩展性平台 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业－雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天公布收购一系列家喻户晓的药品品牌，包括「十灵丹」、「十灵油」及「伤风克」。
more info >> |
|
|
雅各臣收購「十靈丹」、「十靈油」及「傷風克」建立具擴展性平台 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業－雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天公佈收購一系列家喻戶曉的藥品品牌，包括「十靈丹」、「十靈油」及「傷風克」。
more info >> |
|
|
Jacobson Pharma to Acquire Saplingtan, Shiling Oil & Col-gan Tablet; Creating an Expandable Proprietary Medicine Platform |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its acquisition of a family of popular household brands, namely, Saplingtan, Shiling Oil and Col-gan Tablet.
more info >> |
|
| Tuesday, December 13, 2016 |
|
|
雅各臣公布完成收购「何济公」之100%权益 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业—雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天宣布完成收购目标集团（由「嘉伦药业有限公司」、「永生药业有限公司」及「香港何济公药厂有限公司」组成），该目标集团拥有传统居家品牌「何济公」之100%权益，总代价为568,000,000港元。 more info >> |
|
|
雅各臣公佈完成收購「何濟公」之100%權益 |
| 從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業—雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天宣佈完成收購目標集團（由「嘉倫藥業有限公司」、「永生藥業有限公司」及「香港何濟公藥廠有限公司」組成），該目標集團擁有傳統居家品牌「何濟公」之100%權益，總代價為568,000,000港元。 more info >> |
|
|
Jacobson Pharma Announces Acquisition of 100% Interest in Ho Chai Kung Brand |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary Chinese medicines, today announces the acquisition of 100% interest in a Target Group (comprising "Karen Pharmaceutical Company Limited" more info >> |
|
| Wednesday, November 23, 2016 |
|
|
雅各臣公布二零一六年中期业绩 |
从事非专利药及中成药研发、生产、市场推广及销售的领先企业，以及香港最大的非专利药公司─雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633 ）今天公布公司及附属公司（统称「集团」）截至二零一六年九月三十日止六个月（「报告期」）的未经审核中期业绩。
more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱重工、新しい経営方針「ITO」の実践による優秀事例を顕彰
Mar 18, 2026 14:00: JST
|
|
|
GUOQUAN FOOD (2517.HK) Surging core operating profit, Four Stores Jointly Advancing with Concerted Efforts for Long-Term Growth
Mar 18, 2026 13:54 HKT/SGT
|
|
|
FILMART and EntertainmentPulse 2026 open today
Mar 18, 2026 14:42 JST
|
|
|
Chuangxin Industries Announces 2025 Annual Results
Mar 18, 2026 09:30 HKT/SGT
|
|
|
創新實業公佈2025年全年業績 收入及利潤穩步增長
Mar 18, 2026 09:00 HKT/SGT
|
|
|
创新实业公布2025年全年业绩 收入及利润稳步增长
Mar 18, 2026 00:04 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 23:05: JST
|
|
|
Maxon、リアルタイム建築ビジュアライゼーションソリューションでAEC市場に正式参入
Mar 17, 2026 23:05: JST
|
|
|
Maxon, 실시간 Archviz 솔루션으로 AEC 시장 공식 진출
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出即時Archviz解決方案，正式進軍AEC市場
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出实时Archviz解决方案，正式进军AEC市场
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 22:05 HKT/SGT
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00: JST
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00 HKT/SGT
|
|
|
Geo Energy's Integrated Infrastructure Project Achieves 80% Completion; Secures Two Binding Term Sheets with Third Parties for 9 Million Tonnes Annual Haulage; Coal Prices Surge Amid Global Tensions
Mar 17, 2026 22:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
